Search NEL Online

Journal Article 2014; 35(Suppl 2): 155-157 PubMed PMID: 25638380 Citation  Keywords:  Adjuvants, Immunologic:pharmacology, Animals, Cytokines:metabolism, Female, Hemocyanin:pharmacology, Mice, Mice, Inbred BALB C, Models, Animal, Oximes:pharmacology, Pyridinium Compounds:pharmacology,.   

OBJECTIVES: HI-6 or asoxime in some sources is an antidotum for nerve agents. In recent experiments, implication of HI-6 in immunity response was proved; however, the issue was not studied in details. In this experiment, role of cytokines in HI-6 impact on immunity was searched. DESIG N: BALB/c mice were exposed to saline, HI-6 in a dose 1-100 mg/kg and/or 1 keyhole limpet hemocyanin (KLH) 1 mg/kg. Mice were sacrificed 21 days after experiment beginning and interleukins (IL) 1, 2, 4, 6 were determined by Enzyme Linked Immunosorbent Assay (ELISA).

RESULTS: The animals had no pathological manifestation. From the tested cytokines, no significant alteration was found for the IL-1, IL-4 and IL-6. IL-2 was significantly increased in a dose response manner.

CONCLUSIONS: The experimental data well correlates with the previous work where HI-6 caused increase of antibodies production. HI-6 is suitable to be used as an adjuvant whenever immunity should be pharmacologically altered.

...

Read abstract  Full text PDF

Journal Article 2012; 33(Suppl 3): 96-106 PubMed PMID: 23353851 Citation  Keywords:  Adjuvants, Immunologic:pharmacology, Animal Feed, Animals, Blood Proteins:metabolism, Dose-Response Relationship, Drug, Fisheries:methods, Immune System:drug effects, Oncorhynchus mykiss:blood, Pleurotus:chemistry, beta-Glucans:pharmacology,.   

OBJECTIVES: Effect of long-term oral administration of three different concentrations (0.5, 1.0, and 2.0%) of micronized β-1.3/1.6-D-glucan derived from oyster mushroom (Pleurotus ostreatus, Hiratake) on biometrical, haematological, biochemical, and immunological indices of half-year-old rainbow trout (Oncorhynchus mykiss) was assessed in the study.

DESIGN: Rainbow trout were feed commercial feed pellets containing β-1.3/1.6-D-glucan in the concentrations of 0.5, 1.0, and 2.0% for 85 days. Biometrical indices consisted in total and standard length, body and liver weight, from which derived somatic parameters such as Fulton´s condition factor and hepatosomatic index were calculated. Haematological parameters were evaluated according to unified methods for haematological examination in fish. Plasma biochemical profile was analysed using biochemical analyser Konelab 20i and Easy Lyte Analyzer. A phagocyte cells metabolic activity (induced chemiluminescence of phagocytes) was determined as an immunological parameter by a microplate luminometric method on Immunotech LM-01T.

RESULTS: No clinical signs of behavioral, respiratory, or neurologic distress were observed in rainbow trout. Fish showed normal feeding behavior. As for biometric parameters, no significant changes in total and standard length, body weight, liver weight, as well as in condition factor and hepatosomatic index of experimental and control fish were found. In the course of the study, weight gains in rainbow trout were similar and continuous. Shifts in PCV (p<0.05), haemoglobin (p<0.05), and MCHC (p<0.01) were found within haematological indices. Plasma concentration of glucose, lactate, total protein, cholesterol, calcium, natrium, potassium (all p<0.05), albumins and chlorides (both p<0.01), as well as catalytic activities of ALT and AST (both p<0.05) were changed in the course of the study. A phagocyte cells metabolic activity (luminol-induced chemiluminescence) in rainbow trout was not altered by oyster mushroom β-1.3/1.6-D-glucan administration.

CONCLUSION: After long-term oral administration of three concentrations of micronized β-1.3/1.6-D-glucan derived from oyster mushroom (Pleurotus ostreatus, Hiratake) shifts in haematological and biochemical profiling were found in half-year-old rainbow trout (O. mykiss) in environmental conditions of a commercial rainbow trout fishery. Biometrical indices were not found significantly altered. No specific effect of β-glucan on immune system response of rainbow trout was found in the study. The use of β-glucan in prosperous, clinically healthy aquaculture is still an issue, nevertheless, its use in breedings endangered by stress stimuli, infectious diseases or adverse environmental factors is indisputable....

Read abstract  Full text PDF

Journal Article 2003; 24(6): 440-444 PubMed PMID: 15073572 Citation  Keywords:  Adjuvants, Immunologic:pharmacology, Breast Neoplasms, Cell Division:drug effects, Cell Line, Tumor:cytology, Drug Interactions, Estradiol:pharmacology, Estrogen Receptor alpha, Estrogen Receptor beta, Female, Gene Expression Regulation, Neoplastic:drug e.   

OBJECTIVES: Detection of the antiestrogenic effect of melatonin on various breast cancer cell lines and its dependence of the differential expression of estrogen receptors (ERalpha and ERbeta) and melatonin receptors (mt1 and RZRalpha).

SETTING AND DESIGN: Dose-response curves of estradiol were determined in 6 different breast cancer cell lines using a colorimetric proliferation assay in the absence or presence of various melatonin concentrations.

METHODS: In order to detect the minor growth inhibitory effect of melatonin, a simple yet novel approach was employed: instead of incubating cells at single estradiol-concentrations at increasing melatonin levels, breast cancer cells were grown in microwell-plates for 4 days at increasing concentrations of estradiol (10(-12)M - 10(-10)M) in the absence or presence of melatonin (10(-9)M - 10(-8)M). Cell number was determined using Alamar blue and colorimetry. RT-PCR was performed for the expression of ERalpha, ERbeta, RZRalpha and mt1.

RESULTS: Melatonin at concentrations of 10(-9)M and 5 x 10(-9)M shifted the dose-response curves of estradiol to higher concentrations. Responsiveness to melatonin depended on expression of ERalpha but not on ERbeta. mRNA of ERbeta was not detectable in the breast cancer cell lines used. Only small amounts of mt1 transcripts were detectable in MCF-7 cells of one source. In MCF-7 cells transfected with the mt1 gene and in an ovarian cancer cell line mt1 was expressed at significant levels. RZRalpha was expressed in all tested cell lines at different amounts.

CONCLUSION: The growth of all ERalpha-positive breast cancer cell lines can be inhibited by melatonin. The effect in most cell lines is weak yet clearly reproducible. RZRalpha clearly contributes to the growth inhibitory effect of melatonin....

Read abstract  Full text PDF

Journal Article 2002; 23(4): 321-324 PubMed PMID: 12195234 Citation  Keywords:  Adjuvants, Immunologic:pharmacology, Animals, Carcinogenicity Tests, Dehydroepiandrosterone:pharmacology, Estradiol:pharmacology, Female, Galanin:genetics, Gene Expression:drug effects, Pituitary Gland, Anterior:drug effects, Prolactin:blood, RNA, Messeng.   

OBJECTIVES: The effects of dehydroepiandrosterone (DHEA) on galanin (GAL) and prolactin (PRL) mRNA expression in the anterior pituitary of Fischer 344 rats were studied, taking in consideration that: (1) DHEA is an androgen with estrogenic activity on pituitary lactotrophs; (2) estrogens induce prolactinomas in Fischer 344 rats; and (3) GAL has been considered the main mediator of estrogen-induced lactotroph proliferation.

DESIGN: Female rats were ovariectomized and used as controls or treated during 2 weeks with DHEA (500 mg/kg/day or 5 mg/kg/day or 50 mg/kg/day) or estradiol (E2, 50 microg/kg/day), as a positive control for pituitary growth and GAL induction. GAL and PRL mRNA expression were studied by in situ hybridization.

RESULTS: Both DHEA and E2 induced PRL mRNA synthesis. However, DHEA neither produced pituitary enlargement nor GAL induction, in contrast to E2.

CONCLUSIONS: Our results shows that GAL is not involved in the estrogenic activity of DHEA on pituitary lactotrophs, and suggest that DHEA effects are exerted directly on the PRL gene or through another mechanism(s) not related to GAL....

Read abstract